Axitinib News and Research

RSS
Study shows potential of avelumab plus axitinib as new treatment option for patients with advanced RCC

Study shows potential of avelumab plus axitinib as new treatment option for patients with advanced RCC

Recycling existing drugs may help fight several types of cancer

Recycling existing drugs may help fight several types of cancer

Potential therapeutic approaches to combat chronic myeloid leukemia

Potential therapeutic approaches to combat chronic myeloid leukemia

New clinical trial uses aggressive treatment method for patients with pancreas cancer

New clinical trial uses aggressive treatment method for patients with pancreas cancer

Rabbit virus can be paired with existing drug to deliver more potent punch to brain tumor cells

Rabbit virus can be paired with existing drug to deliver more potent punch to brain tumor cells

First-line TKI adverse event profile has no bearing on second-line RCC treatment choice

First-line TKI adverse event profile has no bearing on second-line RCC treatment choice

First-line axitinib ‘feasible’ in advanced, metastatic RCC

First-line axitinib ‘feasible’ in advanced, metastatic RCC

Sorafenib, sunitinib provide no benefit to patients with locally advanced kidney cancer

Sorafenib, sunitinib provide no benefit to patients with locally advanced kidney cancer

Researchers identify axitinib as promising candidate to treat drug-resistant leukaemia

Researchers identify axitinib as promising candidate to treat drug-resistant leukaemia

Long-term axitinib in RCC effective with ‘controllable’ toxicities

Long-term axitinib in RCC effective with ‘controllable’ toxicities

RCC renal function independent of axitinib-induced proteinuria

RCC renal function independent of axitinib-induced proteinuria

Nonlinear correlation between axitinib dose, dBP increase

Nonlinear correlation between axitinib dose, dBP increase

Quality of life maintained during mRCC TKI therapy

Quality of life maintained during mRCC TKI therapy

Adopting a comprehensive and integrative healing strategy for cancer

Adopting a comprehensive and integrative healing strategy for cancer

Neoadjuvant targeted treatment shows feasibility for limited clear-cell RCC

Neoadjuvant targeted treatment shows feasibility for limited clear-cell RCC

Pfizer and Merck join forces to explore therapeutic potential of anti-PD-1 therapy

Pfizer and Merck join forces to explore therapeutic potential of anti-PD-1 therapy

Exelixis starts phase 3 pivotal trial of cabozantinib for treatment of metastatic renal cell carcinoma

Exelixis starts phase 3 pivotal trial of cabozantinib for treatment of metastatic renal cell carcinoma

Sunitinib does not cause lingering risks for cancer patients after their treatment ends

Sunitinib does not cause lingering risks for cancer patients after their treatment ends

Acceleron commences dalantercept phase 2 study in metastatic renal cell carcinoma

Acceleron commences dalantercept phase 2 study in metastatic renal cell carcinoma

Phase 3 study of INLYTA fails to meet primary endpoint in treatment-naïve patients with RCC

Phase 3 study of INLYTA fails to meet primary endpoint in treatment-naïve patients with RCC